Evidence map›Paper›PMID 33964729›Full record

ReviewCurrent opinion in pharmacology2021

Beyond the AMPA receptor: Diverse roles of SynDIG/PRRT brain-specific transmembrane proteins at excitatory synapses.

Elva Dίaz

Open access · hybridAbstract readReview
In one paragraph

Review in Current opinion in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Elva DίazDepartment of Pharmacology, University of California Davis School of Medicine, 451 Health, Sciences Drive, Davis, CA 95616, USA. Electronic address: ediaz@ucdavis.edu.
University of California, Davis · US

Funding

SynDIG1/Prrt1 regulation of extrasynaptic GluA1-containing AMPARs during plasticityR01MH119347 · NIMH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DIAZ, ELVA D, HELL, JOHANNES W · 2019 to 2024
$3.3M
NIMH NIH HHS R01 MH119347
6 · The paper itself

Abstract

α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors (AMPARs) are responsible for fast excitatory transmission in the brain. Deficits in synaptic transmission underlie a variety of neurological and psychiatric disorders. However, drugs that target AMPARs are challenging to develop, given the central role played in neurotransmission. Targeting AMPAR auxiliary factors offers an innovative approach for achieving specificity without altering baseline synaptic transmission. This review focuses on the SynDIG/proline-rich transmembrane protein (PRRT) family of AMPAR-associated transmembrane proteins. Although these factors are related based on sequence similarity, the proteins have evolved diverse actions at excitatory synapses that are not limited to the traditional role ascribed to an AMPAR auxiliary factor. SynDIG4/PRRT1 acts as a typical AMPAR auxiliary protein, while PRRT2 functions at presynaptic sites to regulate synaptic vesicle dynamics and is the causative gene for neurological paroxysmal disorders in humans. SynDIG/PRRT proteins are members of a larger superfamily that also include antiviral proteins known to restrict fusion between host and viral membranes and share some interesting characteristics.

Indexed as

Receptors, AMPASynapsesBrainHumansMembrane ProteinsSynaptic TransmissionMembrane ProteinsReceptors, AMPAAMPA receptor auxiliary factorCP-AMPARsExcitatory synapsePalmitoylationParoxysmal kinesigenic dyskinesiaPRRT1PRRT2Synaptic plasticitySynDIG1SynDIG4

Identifiers

PMID33964729
PMCPMC8195862
OpenAlexW3159599675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.